Essay Title: 

Integrated Strategy Project – Bristol-Myers Squibb Pharmaceutical Ltd

March 24, 2016 | Author: | Posted in anthropology, life sciences

Bristol Myers Squibb

Bristol Myers Squibb was formed in 1887 when McLaren Bristol and John Ripley Myers bought the Clinton pharmaceutical Company in Clinton New York

In 1900 Bristol-Myers broke through into the black — it has remained there ever since . In 1924 , gross profits topped 1 million for the first time in Bristol-Myers ‘ history . The company ‘s products were then sold in 26 countries . At this point , the shares held by John Myers ‘s heirs became available for sale , triggering a series of moves that in 1929 turned Bristol-Myers into [banner_entry_middle]

a publicly held company , listed on the New York Stock Exchange

The postwar depression prompted Bristol-Myers to jettison its pharmaceutical business and devote itself entirely to its specialties Sal Hepatica and Ipana , its two big winners , and a dozen or so assorted toiletries , antiseptics and cough syrups . By the end of the war , it was clear that penicillin and other antibiotics represented an immense opportunity for Bristol-Myers

In 1921 the Squibb Company coined its slogan “The priceless ingredient in every product is the honor and integrity of its maker which is now the corporate slogan of Bristol Myers Squibb

In 1989 Bristol-Myers merged with Squibb , creating a global leader in the health care industry . The merger created what was then the world ‘s second-largest pharmaceutical enterprise . BMS is now ranked 8 in the pharma sector

Current Drugs , Issues and Interests

The Company operates in three segments : Pharmaceuticals , Nutritionals and Other Healthcare . The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business . The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson , primarily an infant formula and children ‘s nutritional business . The Other Healthcare segment consists of ConvaTec , Medical Imaging and Consumer Medicines (United States and Canada ) businesses

In 1991 , the company received U .S . Food and Drug Administration (FDA approval in the U .S . for Videx (R (didanosine ) also known as ddI , making it the second medicine available for treating HIV infection (the other being AZT . Other approvals that year included an antibiotic , Cefzil (R (cefprozil two cardiovascular agents , Pravachol (R (pravastatin sodium ) Tablets and Monopril (R (fosinopril sodium ) Tablets and a central nervous system drug , Stadol NS (R (butorphanol tartrate ) C-IV

In that same year , the companies signed a Cooperative Research and Development Agreement with the National Cancer Institute to research and develop a new compound for treating certain types of cancer . This compound , TAXOL (R (paclitaxel ) Injection , immediately was established as the company ‘s top research priority . Bristol-Myers Squibb invested hundreds of millions of dollars to supply TAXOL in sufficient quantities for clinical trials , to prepare data for regulatory submission and to develop alternative sources of TAXOL (which originally was derived from the bark of an endangered tree , the Pacific Yew . TAXOL launched in 1993 and quickly became one of the world ‘s most widely used cancer treatments . For a few years BMS held the exclusive rights to harvest the bark of the endangered yew trees on US soil , the tree ‘s… [banner_entry_footer]

Comments Off on Integrated Strategy Project – Bristol-Myers Squibb Pharmaceutical Ltd

Author:

This author has published 9190 articles so far. More info about the author is coming soon.

Comments are closed.